// Script to change toggle default state //G Smith second script to show/hide Leadership sections

Delivery

We have pioneered a new category of drug delivery of therapeutics for CNS-based diseases with the potential ability to shift the outcomes for patients around the globe.

Intranasal Delivery

Intranasal delivery has been used for therapeutic reasons for centuries. As the nose is one of the primary gateways for the respiratory system, the focus has been mainly on the delivery of therapeutics for treating topical symptoms of seasonal rhinitis or infectious diseases in the nasal cavity, the throat, and the lungs. Intranasal delivery of medications offers many advantages over standard systemic delivery systems, such as its non-invasive character, fast onset of action, and, in many cases, reduced side effects due to a more targeted delivery.

In 1991, focus began to shift with studies demonstrating that intranasal delivery of therapeutics could benefit CNS-based issues. Since 2015, intranasal treatment options for providing seizure control for patients with epilepsy have been approved by the FDA. Recently, intranasal delivery of benzodiazepines has been shown to reduce time to drug administration and cessation of epileptic seizures in actively seizing patients.

Advantages of Intranasal Delivery

Unlike traditional IV or oral delivery of therapeutics for CNS-based diseases, which rely on the circulatory system for transport, intranasal delivery uses the olfactory or trigeminal nerve pathways as a conduit for the therapeutic to be delivered into the Brain’s Cerebrospinal fluid (CSF).

Many studies have shown that small molecule therapeutics in aerosol form can pass through the olfactory mucosa to CNS-connected nerve tissue. Once in the nerve pathway, the therapeutic is picked up into the CSF, bypassing the BBB and allowing the therapeutic to reach a targeted disease site, such as a cancer tumor.

Intranasal drug delivery is non-invasive and can be easily administered by or for the patient, reducing treatment costs and without systemic side effects. Intranasal delivery provides a rapid onset of action and avoidance of first-pass metabolism efficacy decrease.

Proven Success

Over the past five years, NeOnc Technologies has performed multiple studies looking at the viability of using its proprietary formulation of POH as both a standalone therapeutic for CNS-based disease treatment and as a solvent for creating combinatorial formulations for other therapeutics. In all of the studies, the NeOnc formulations have suggested to be advantageous in providing a positive impact on disease treatment. In the studies involving intranasal delivery of NEO100 or NEO100 combinatorial, the results have suggested that delivery is faster and uptake of the therapeutic into the CSF and brain tissue was higher than with traditional delivery methodologies.